Moneycontrol PRO
Open App
you are here: HomeNewsIndia

ICMR says Remdesivir 'not a life-saving drug', calls for safe and rational usage

The evidence so far suggests that Remdesivir reduces the duration of hospital stay, the ICMR said, adding that it "should be administered in hospital setting only".

April 21, 2021 / 10:12 PM IST

Amid the sharp surge in Remdesivir demand across the country, the Indian Council of Medical Research (ICMR) said on April 20 that the antiviral medication is "not a life-saving drug".

The top medical advisory body called for "safe and rational" usage of Remdesivir, stressing that it has been granted emergency use authorisation only as an "experimental investigational drug", News18 reported. It should be administered only in selected clinical condition of COVID-19, it said.

The evidence so far suggests that Remdesivir reduces the duration of hospital stay, the ICMR reportedly said, adding that it "should be administered in hospital setting only".

"Unnecessary/irrational use of Remdesivir could be harmful," the channel quoted the medical research body as stating.

"Remdesivir is advised for hospitalised patients who are moderately sick and receiving oxygen. It is to be given for a total period of five days only and within the 10 days of illness," it further added.


COVID-19 Vaccine

Frequently Asked Questions

View more
How does a vaccine work?

A vaccine works by mimicking a natural infection. A vaccine not only induces immune response to protect people from any future COVID-19 infection, but also helps quickly build herd immunity to put an end to the pandemic. Herd immunity occurs when a sufficient percentage of a population becomes immune to a disease, making the spread of disease from person to person unlikely. The good news is that SARS-CoV-2 virus has been fairly stable, which increases the viability of a vaccine.

How many types of vaccines are there?

There are broadly four types of vaccine — one, a vaccine based on the whole virus (this could be either inactivated, or an attenuated [weakened] virus vaccine); two, a non-replicating viral vector vaccine that uses a benign virus as vector that carries the antigen of SARS-CoV; three, nucleic-acid vaccines that have genetic material like DNA and RNA of antigens like spike protein given to a person, helping human cells decode genetic material and produce the vaccine; and four, protein subunit vaccine wherein the recombinant proteins of SARS-COV-2 along with an adjuvant (booster) is given as a vaccine.

What does it take to develop a vaccine of this kind?

Vaccine development is a long, complex process. Unlike drugs that are given to people with a diseased, vaccines are given to healthy people and also vulnerable sections such as children, pregnant women and the elderly. So rigorous tests are compulsory. History says that the fastest time it took to develop a vaccine is five years, but it usually takes double or sometimes triple that time.

View more

Also read: Remdesivir not a magic bullet, no use if administered to asymptomatic patients: AIIMS Director Randeep Guleria

A day earlier, All India Institute of Medical Sciences (AIIMS) chief Dr Randeep Guleria also called for similar restraint in the usage of Remdesivir.

"It's important to understand that Remdesivir is not a magic bullet and isn't a drug that decreases mortality. We may use it as we don't have an anti-viral drug," he said.

Remdesivir should only be given to patients who are hospitalised, had a fall in oxygen saturation and have infiltrates on the chest X-ray or CT-scan, the AIIMS chief explained.

The demand for the drug has shot up since India was hit by the second wave of the pandemic. States with high caseload have urged the Centre to expedite the supply. Maharashtra, the worst-affected, requires 40,000-50,000 Remdesivir vials a day, Chief Minister Uddhav Thackeray said on April 13.
first published: Apr 20, 2021 11:11 pm
ISO 27001 - BSI Assurance Mark